

INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Not for submission under 37 CFR 1.99)	Application Number		10632340
	Filing Date		2003-08-01
	First Named Inventor	Cornelia J. Forster	
	Art Unit	1624	
	Examiner Name	Venkataraman Balasubramanian	
	Attorney Docket Number	VPI/02-119 US	

U.S. PATENTS							Remove
Examiner Initial*	Cite No	Patent Number	Kind Code ¹	Issue Date	Name of Patentee or Applicant of cited Document	Pages, Columns, Lines where Relevant Passages or Relevant Figures Appear	
	1	6653301		2003-25-11	Vertex Pharmaceuticals Incorporated		
	2	6989385		2006-24-01	Vertex Pharmaceuticals Incorporated		
	3	6664247		2003-16-12	Bebbington et al.		
	4	6653300		2003-25-11	Bebbington et al.		
	5	7087603		2006-08-08	Bebbington et al.		
	6	6656939		2003-02-12	Bebbington et al.		
	7	3755322		1973-08-28	Ciba-Geigy Corporation		
	8	6841579		2005-11-01	Sugen, Inc.		

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**
(Not for submission under 37 CFR 1.99)

Application Number	10632340
Filing Date	2003-08-01
First Named Inventor	Comella J. Forster
Art Unit	1624
Examiner Name	Venkataraman Balasubramanian
Attorney Docket Number	VP/02-119 US

9	6093716		2000-25-07	Celltech Therapeutics, Limited	
10	6277989		2001-08-21	Scios, Inc.	
11	6579883		2003-06-17	Celltech R&D Limited	
12	6660731		2003-12-09	Vertex Pharmaceuticals Incorporated	
13	6184226		2001-02-06	Scios, Inc.	
14	6589958		2003-07-08	Bristol-Myers Squibb Pharma Company	
15	7008948		2006-03-07	Vertex Pharmaceuticals Incorporated	
16	6686452		2004-02-24	Vertex Pharmaceuticals Incorporated	
17	7098330		2006-08-29	Vertex Pharmaceuticals Incorporated	
18	6660731		2003-12-09	Vertex Pharmaceuticals Incorporated	
19	6613776		2003-09-02	Vertex Pharmaceuticals Incorporated	

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**
(Not for submission under 37 CFR 1.99)

Application Number	10632340
Filing Date	2003-08-01
First Named Inventor	Cornelia J. Forster
Art Unit	1624
Examiner Name	Venkataraman Balasubramanian
Attorney Docket Number	VP/02-119 US

20	6638926	2003-10-28	Vertex Pharmaceuticals Incorporated	
21	6610677	2003-08-26	Vertex Pharmaceuticals Incorporated	
22	7115739	2006-10-03	Vertex Pharmaceuticals Incorporated	
23	7179826	2007-02-20	Vertex Pharmaceuticals Incorporated	
24	6846928	2005-01-25	Vertex Pharmaceuticals Incorporated	
25	7091343	2006-08-15	Vertex Pharmaceuticals Incorporated	
26	4540698	1985-09-10	Mitsui Toatsu Chemicals Incorporated	
27	4711951	1987-12-08	Pharmacia Aktiebolag	
28	5124441	1992-06-23	Pharmacia Aktiebolag	
29	6562971	2003-05-13	BASF Aktiengesellschaft	
30	6558657	2003-05-06	Mandeville, III et al.	

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**
(Not for submission under 37 CFR 1.99)

Application Number	10632340
Filing Date	2003-08-01
First Named Inventor	Comella J. Forster
Art Unit	1624
Examiner Name	Venkataraman Balasubramanian
Attorney Docket Number	VPI/02-119 US

31	6495582		2002-12-17	Hale et al.	
32	6528509		2003-03-04	Hale et al.	

If you wish to add additional U.S. Patent citation information please click the Add button.

Add

U.S.PATENT APPLICATION PUBLICATIONS

Remove

Examiner Initial*	Cite No	Publication Number	Kind Code ¹	Publication Date	Name of Patentee or Applicant of cited Document	Pages, Columns, Lines where Relevant Passages or Relevant Figures Appear
	1	20020065270		2002-05-30	Bristol-Myers Squibb Company	
	2	20010018436		2001-08-30	Tularik Inc.	
	3	20020052386		2002-05-02	Armistead et al.	
	4	20050038023		2005-02-17	Bebbington et al.	
	5	20040157893		2004-08-12	Bebbington et al.	
	6	20030069239		2003-04-10	Cytovia, Inc.	
	7	20030069248		2003-10-04	Chakravarty et al.	

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**
(Not for submission under 37 CFR 1.99)

Application Number	10632340
Filing Date	2003-08-01
First Named Inventor	Comelia J. Forster
Art Unit	1624
Examiner Name	Venkataraman Balasubramanian
Attorney Docket Number	VP/02-119 US

8	20030087922		2003-05-08	Bethiel et al.	
9	20030187002		2003-10-02	Mortlock et al.	
10	20060270660		2006-11-30	Chamier et al.	
11	20030078166		2003-04-24	Davies et al.	
12	20030064981		2003-04-03	Knegtel et al.	
13	20040002496		2004-01-01	Bebbington et al.	
14	20030199526		2003-10-23	Choquette et al.	
15	20030092714		2003-05-15	Cao et al.	
16	20040229875		2004-11-18	Cao et al.	
17	20030096816		2003-05-22	Cao et al.	
18	20040023963		2004-02-05	Cao et al.	

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**
(Not for submission under 37 CFR 1.99)

Application Number	10632340
Filing Date	2003-06-01
First Named Inventor	Cornelia J. Forster
Art Unit	1624
Examiner Name	Venkataraman Balasubramanian
Attorney Docket Number	VPI/02-119 US

If you wish to add additional U.S. Published Application citation information please click the Add button. [Add](#)

FOREIGN PATENT DOCUMENTS								Remove
Examiner Initial*	Cite No	Foreign Document Number ³	Country Code ² j	Kind Code ⁴	Publication Date	Name of Patentee or Applicant of cited Document	Pages, Columns, Lines where Relevant Passages or Relevant Figures Appear	T ⁵
	1	136976	EP		1985-04-10	Ciba-Geigy AG		<input type="checkbox"/>
	2	0302312	EP		1989-02-08	Bayer AG		<input type="checkbox"/>
	3	0019811	EP		1980-12-10	Ciba-Geigy AG		<input type="checkbox"/>
	4	2052487	GB		1981-01-28	Ciba-Geigy AG		<input type="checkbox"/>
	5	06-65237	JP		2007-10-25	Nissan Chem. Ind., Ltd.		<input checked="" type="checkbox"/>
	6	10-130150	JP		1998-05-19	Dainippon Pharmaceutical Co., Ltd.		<input checked="" type="checkbox"/>
	7	0012487	WO		2000-03-09	Scios Inc.		<input type="checkbox"/>
	8	0144242	WO		2001-06-21	Bristol-Myers Squibb Co.		<input type="checkbox"/>
	9	0247690	WO		2003-06-20	Cytovia, Inc.		<input type="checkbox"/>

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**
(Not for submission under 37 CFR 1.99)

Application Number	10632340
Filing Date	2003-08-01
First Named Inventor	Cornelia J. Forster
Art Unit	1624
Examiner Name	Venkataraman Balasubramanian
Attorney Docket Number	VP1/02-119 US

10	0224667	WO		2003-03-28	Merck Patent GMBH		<input type="checkbox"/>
11	9614843	WO		2008-07-13	Cor Therapeutics, Inc.		<input type="checkbox"/>
12	9509851	WO		1995-04-13	Ciba-Geigy AG		<input type="checkbox"/>
13	9709325	WO		1997-03-13	Signal Pharmaceuticals, Inc.		<input type="checkbox"/>
14	9719065	WO		1997-05-29	Celltech Therapeutics Limited		<input type="checkbox"/>
15	9811095	WO		1998-03-19	Celltech Therapeutics Limited		<input type="checkbox"/>
16	9941253	WO		1999-08-19	Tularik Inc.		<input type="checkbox"/>
17	0140215	WO		2001-06-07	Pfizer Products Inc.		<input type="checkbox"/>
18	0147879	WO		2001-07-05	Icos Corporation		<input type="checkbox"/>
19	0164655	WO		2001-09-07	AstraZeneca AB		<input type="checkbox"/>
20	0413140	WO		2004-02-14	Vertex Pharmaceuticals Incorporated		<input type="checkbox"/>

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**
(Not for submission under 37 CFR 1.99)

Application Number	10632340
Filing Date	2003-08-01
First Named Inventor	Cornelia J. Forster
Art Unit	1624
Examiner Name	Venkataraman Balasubramanian
Attorney Docket Number	VP/02-119 US

21	0250066	WO		2002-06-27	Vertex Pharmaceuticals Incorporated		<input type="checkbox"/>
22	0279197	WO		2002-10-10	Vertex Pharmaceuticals Incorporated		<input type="checkbox"/>
23	0400833	WO		2003-12-31	Vertex Pharmaceuticals Incorporated		<input type="checkbox"/>
24	9208715	WO		1992-05-29	Nissan Chemical Industries, Ltd.		<input type="checkbox"/>
25	9515758	WO		1995-06-15	Rhonepoulenc Rorer Pharmaceuticals Inc.		<input type="checkbox"/>
26	9802434	WO		1996-01-22	Glaxo Group Limited		<input type="checkbox"/>
27	9947154	WO		1999-09-23	Cytovia, Inc.		<input type="checkbox"/>
28	0059509	WO		2000-10-12	Novartis AG		<input type="checkbox"/>
29	0078757	WO		2000-12-28	Shionogi Bioresearch Corp.		<input type="checkbox"/>
30	0112621	WO		2001-02-22	Vertex Pharmaceuticals Incorporated		<input type="checkbox"/>
31	0139777	WO		2001-06-07	OSI Pharmaceuticals, Inc.		<input type="checkbox"/>

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Not for submission under 37 CFR 1.99)

Application Number	10632340
Filing Date	2003-08-01
First Named Inventor	Comelia J. Forster
Art Unit	1624
Examiner Name	Venkataraman Balasubramanian
Attorney Docket Number	VP/02-119 US

32	9918781	WO		1999-04-22	Cytovia, Inc.		<input type="checkbox"/>
33	0125220	WO		2001-04-12	Kinetix Pharmaceuticals Inc.		<input type="checkbox"/>
34	9965897	WO		1999-12-23	Chiron Corporation		<input type="checkbox"/>
35	0038675	WO		2000-07-06	Smith Klein Beecham, PLC		<input type="checkbox"/>
36	9816502	WO		1998-04-23	Warner-Lambert Company		<input type="checkbox"/>

If you wish to add additional Foreign Patent Document citation information please click the Add button

NON-PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc), date, pages(s), volume-issue number(s), publisher, city and/or country where published.	T5
	1	Afonso, M. et al., "GSK-3 Inhibitors: Discoveries and Developments", Current Medicinal Chemistry, 11, 755-763 (2004).	<input type="checkbox"/>
	2	Anonymous, "Vertex Inhibitors of Aurora-2, glycogen synthase kinase-3 and Src Kinase", Expert Opin. Ther. Patents, 14(3): 439-443 (2004).	<input type="checkbox"/>
	3	Baig, G.U. et al., "Triazines and Related Products. Part 28' Conversion of 3-Aryl-4-(2-cyanophenyl) triazines into 3-Arylquinoxalines" J. Chem. Soc. Perkin Trans. 1, 3765-2766 (1984).	<input type="checkbox"/>
	4	Bischoff, J.R., et al., "A homologue of Drosophila aurora kinase is oncogenic and amplified in human colorectal cancers", The EMBO Journal, 17(11): 3052-3065 (1998).	<input type="checkbox"/>

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**
(Not for submission under 37 CFR 1.99)

Application Number	10632340
Filing Date	2003-08-01
First Named Inventor	Comella J. Forster
Art Unit	1624
Examiner Name	Venkataraman Balasubramanian
Attorney Docket Number	VP/02-119 US

5	Bischoff, J.R., et al., "The Aurora/Ipl1p kinase family: regulators of chromosome segregation and cytokinesis", CELL BIOLOGY, 9, 454-459 (1999).	<input type="checkbox"/>
6	Brunswick, D.J. et al., "Cyclic Amidines. Part XXII. Novel Isomerism of Disubstituted Tricycloquinazolines and Molecular Orientations in Carcinogenesis", J. Chem. SOC. (C), 2641-2647 (1970).	<input type="checkbox"/>
7	Wolff, M.E., "Burger's Medicinal Chemistry and Drug Discovery," 5th ed., Vol. 1: Principles and Practice, 975-977 (1995).	<input type="checkbox"/>
8	Cohen, P. et al., "The renaissance of GSK3," Nat. Rev. Mol. Biol., 2, 769-776 (2001).	<input type="checkbox"/>
9	Eldor-Finkelstein, H. et al., "Challenges and opportunities with glycogen synthase kinase-3 inhibitors for insulin resistance and Type 2 diabetes treatment," Expert Opinion on Investigational Drugs, 12(9): 1511-1519 (2003).	<input type="checkbox"/>
10	Harrington, E.A. et al., "VX-680, a potent and selective small-molecule inhibitor of the Aurora kinases, suppresses tumor growth in vivo," Nat. Med., 10(3): 262-267 (2004).	<input type="checkbox"/>
11	Heutink, P., "Untangling tau-related dementia", Hum. Mol. Genet., 9(6): 979-986 (2000).	<input type="checkbox"/>
12	Nigg, E.A., "Mitotic Kinases as Regulators of Cell Division and its Checkpoints," Nat. Rev. Mol. Cell Biol., 2: 21-32 (2001).	<input type="checkbox"/>
13	CAPLUS listing Accession No. 1994-292136, Nakajima, Y. et al., "Pyrazoles agricultural and horticultural bactericides," JP 06065237 (1994).	<input type="checkbox"/>
14	DATABASE CA "Online!" Chemical Abstract Service, Columbus, OH, US; Kelarev, V.I. et al., "Synthesis of amino derivatives of 1,3,5-triazine containing 1,3,4-thiadiazole fragments," Database Accession No. 1998:69514 XP002242653 abstract & IZVESTIYA VYSSHIKH UCHEBNIKH ZAVEDENII, KHIMIYA I KHIMICHESKAYA TEKHNLOGIYA, 40(5): 27-32 (1997).	<input type="checkbox"/>
15	Chalmers, D.T. et al., "Corticotrophin-releasing factor receptors: from molecular biology to drug design," TIPS, 17, 769-776 (2001).	<input type="checkbox"/>

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**
(Not for submission under 37 CFR 1.99)

Application Number	10632340
Filing Date	2003-08-01
First Named Inventor	Comella J. Forster
Art Unit	1624
Examiner Name	Venkataraman Balasubramanian
Attorney Docket Number	VPI/02-119 US

16	Kim, L. et al., "GSK3, a master switch regulating cell-fate specification and tumorigenesis," Current Opinion in Genetics & Development, 10:508-514 (2000).	<input type="checkbox"/>
17	Lyrer, P., Schweiz. Med. Woohen Schr., 124(45); 2005-2012 (1994).	<input type="checkbox"/>
18	Banker, G.S. et al., "Modern Pharmaceutics", 451 & 596, 3rd ed., Marcel Dekker, New York (1996).	<input type="checkbox"/>
19	Lovestone, S. et al., "Alzheimer's disease-like phosphorylation of the microtubule-associated protein tau by glycogen synthase kinase-3 in transfected mammalian cells", Curr. Biol., 4(12), 1077-86 (1994).	<input type="checkbox"/>
20	Brownlee, J. et al., "Tau phosphorylation in transgenic mice expressing glycogen synthase kinase-3beta transgene", Neuroreport., 8(15), 3251-5 (1997).	<input type="checkbox"/>
21	Biagi, G. et al., "Synthesis of 4,6 Disubstituted and 4,5,6-Trisubstituted-2-Phenyl-pyrimidines and Their Affinity Towards A1 Adenosine Receptors", Farmaco., 52(1), 61-65 (1997).	<input type="checkbox"/>
22	Ali, N.M. et al., "Palladium-Catalyzed Cross Coupling Reactions of Arylboronic Acids with Pi-Deficient Heteroaryl Chlorides" Tetrahedron, 48 (37), 8117-8126 (1992).	<input type="checkbox"/>
23	Zhang, Z. et al., "Destabilization of β catenin by mutations in presenilin-1 potentiates neuronal apoptosis", Nature, 395, 698-702 (1998).	<input type="checkbox"/>
24	Takashima, K. et al., "Tau Protein Kinase I is Essential for Amyloid β -Protein-Induced Neurotoxicity", PNAS 90, 7789-7793 (1993).	<input type="checkbox"/>
25	Pei, J. et al., "Distribution, Levels, and Activity of Glycogen Synthase Kinase-3 in the Alzheimer Disease Brain", J. Neuropathol Exp., 56, 70-78 (1997).	<input type="checkbox"/>
26	IUPAC Compendium of Chemical Terminology on a definition of "aliphatic compounds" found from http://www.chemsoc.org/chembytes/goldbook/index.htm (last visited on November 18, 2007).	<input type="checkbox"/>

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**
(Not for submission under 37 CFR 1.99)

Application Number	10632340
Filing Date	2003-08-01
First Named Inventor	Comelia J. Forster
Art Unit	1624
Examiner Name	Venkataraman Balasubramanian
Attorney Docket Number	VP1/02-119 US

27	Glossary of Class Names of Organic Compounds and Reactive Intermediates Based on Structure found from http://www.chem.qmul.ac.uk/iupac/class/index.html (last visited on November 18, 2007).	<input type="checkbox"/>
28	Nomenclature found from http://www.cem.msu.edu/~reusch/VirtualText/nomen1.htm (last visited on November 18, 2007).	<input type="checkbox"/>
29	Coghlan, M.P. et al., "Selective small molecule inhibitors of glycogen synthase kinase-3 modulate glycogen metabolism and gene transcription", Chemistry & Biology, 7, 793-83 (2000).	<input type="checkbox"/>
30	Klein, P.S. et al., "A molecular mechanism for the effect of lithium on development", PNAS, 93: 8455-8459 (1996).	<input type="checkbox"/>
31	Cross, D.A.E. et al., "The inhibition of glycogen synthase kinase-3 by insulin or insulin-like growth factor 1 in the rat skeletal muscle cell line L6 is blocked by wortmannin, but not by rapamycin: evidence that wortmannin blocks activation of the mitogen-activated protein kinase pathway in L6 cells between Ras and Raf", Biochem J., 303: 21-26 (1994).	<input type="checkbox"/>
32	Massillon, D. et al., "Identification of the glycogenic compound 5-iodotubercidin as a general protein kinase inhibitor", Biochem J., 299: 123-128 (1994).	<input type="checkbox"/>
33	Fox T. et al., "A single amino acid substitution makes ERK2 susceptible to pyridinyl imidazole inhibitors of p38 MAP kinase", Protein Sci., 7: 2249-2255 (1998).	<input type="checkbox"/>
34	Takayanagi, H. et al., "Suppression of arthritic bone destruction by adenovirus-mediated csk gene transfer to synovocytes and osteoclasts", J. Clin. Invest., 104, 137-146 (1999).	<input type="checkbox"/>
35	Boschelli et al., "Small molecule inhibitors of Src family kinases", Drugs of the Future, 25(7): 717-736 (2000).	<input type="checkbox"/>
36	Talamonti, M.S. et al., "Increase in activity and level of pp60c-src in progressive stages of human colorectal cancer", J Clin Invest., 91(1): 53-60 (1993).	<input type="checkbox"/>
37	Lutz, M.L. et al., "Overexpression and Activation of the Tyrosine Kinase Src in Human Pancreatic Carcinoma", Biochem. Biophys. Res. 243, 503-508 (1998).	<input type="checkbox"/>

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**
(Not for submission under 37 CFR 1.99)

Application Number	10632340
Filing Date	2003-08-01
First Named Inventor	Comelia J. Forster
Art Unit	1624
Examiner Name	Venkataraman Balasubramanian
Attorney Docket Number	VP/02-119 US

38	Rosen, N. et al., "Analysis of pp60c-src Protein Kinase Activity in Human Tumor Cell Lines and Tissues", J Biol. Chem., 261, 13754-13759 (1986).	<input type="checkbox"/>
39	Bo/en, J.B. et al., "Activation of pp60c-src protein kinase activity in human colon carcinoma", PNAS, 84, 2251-2255 (1987).	<input type="checkbox"/>
40	Masaki, T. et al., "pp60c-src Activation in Hepatocellular Carcinoma of Humans and LEC Rats", Hepatology, 27, 1257 (1996).	<input type="checkbox"/>
41	Biscardi, J.S. et al., "c-Src, Receptor Tyrosine Kinases, and Human Cancer", Adv. Cancer Res., 76, 61 (1999).	<input type="checkbox"/>
42	Lynch, S.A. et al., "Increased Expression of the src Proto-Oncogene in Hairy Cell Leukemia and a Subgroup of B-Cell Lymphomas", Leukemia, 7(9), 1416-1422 (1993).	<input type="checkbox"/>
43	Wiener, J.R., "Decreased Src Tyrosine Kinase Activity Inhibits Malignant Human Ovarian Cancer Tumor Growth in a Nude Mouse Model", Clin. Cancer Res., 5, 2164-2170 (1999).	<input type="checkbox"/>
44	Staley, C.A. et al., "Decreased Tumorigenicity of a Human Colon Adenocarcinoma Cell Line by an Antisense Expression Vector Specific for c-Src", Cell Growth Diff., 8, 269-274 (1997).	<input type="checkbox"/>
45	Singhal, N. et al., "Synthesis and Antimalarial Activity of Some New Quinazoline Derivatives", Indian Chem. Soc., 61, 690-693 (1984).	<input type="checkbox"/>
46	Kim, Y.Z. et al., "Synthesis and Antimicrobial Activity of Novel [(3-Aminopyrimidiniumyl)thio]methyl Cephalosporins", J. Med. Chem., 37(22), 3828 - 3833 (1994).	<input type="checkbox"/>
47	Rueeger, H. et al., "Design, synthesis and SAR of a series of 2-substituted 4-amino-quinazoline neuropeptide Y Y5 receptor antagonists", Bioorg. Med. Chem. Lett., 10(11), 1175-1180 (2000).	<input type="checkbox"/>
48	Gershon, H. et al., "Pyrimidines. 7. A Study of the Chlorination of Pyrimidines with Phosphorus Oxychloride in the Presence of N,N-Dimethylaniline", J. Heterocyclic Chem., 21, 1161-1167 (1984).	<input type="checkbox"/>

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**
(Not for submission under 37 CFR 1.99)

Application Number	10632340
Filing Date	2003-08-01
First Named Inventor	Comella J. Forster
Art Unit	1624
Examiner Name	Venkataraman Balasubramanian
Attorney Docket Number	VP/02-119 US

49	Ife, R.J. et al., "Reversible Inhibitors of the Gastric (H ⁺ /K ⁺)-ATPase. 5. Substituted 2,4-Diaminoquinazolines and Thienopyrimidines", J. Med. Chem., 38(14); 2763 – 2773 (1995).	<input type="checkbox"/>
50	Tanzi, K. et al., "Purines. X. Reactivities of Methyl Groups on 9-Phenylpurines : Condensation with an Aldehyde or an Ester, and Oxidation with Selenium Dioxide", Chem. Phar. Bull., 40 (1), 227-229 (1992).	<input type="checkbox"/>

If you wish to add additional non-patent literature document citation information please click the Add button

EXAMINER SIGNATURE

Examiner Signature	Date Considered
--------------------	-----------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through a citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ See Kind Codes of USPTO Patent Documents at www.USPTO.GOV or MPEP 901.04. ² Enter office that issued the document, by the two-letter code (WIPO Standard ST.3). ³ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁴ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ⁵ Applicant is to place a check mark here if English language translation is attached.